Possibilities of correction of lipid-phospholipid disorders in patients with non-alcoholic steatohepatitis against obesity and pathology of the biliary tract.
DOI:
https://doi.org/10.26641/2307-0404.2019.3.181878Keywords:
nonalcoholic steatohepatitis, obesity, lipids, phospholipids, ursodeoxycholic acid, arginine glutamateAbstract
High priority in the pathogenesis and treatment of non-alcoholic steatohepatitis (NASH) is given to disorders of lipid-phospholipid fractions, which are directly related to the functioning of hepatocytes. The aim of the study was to evaluate the effect of various complex treatment regimens on lipid-phospholipid fractions in patients with NASH in combination with obesity (OB) and pathology of the biliary tract (BT) according to a 6-month follow-up. 52 patients with NASH in combination with OB and BT pathology were examined. The control group consisted of 20 practically healthy individuals. The effect of complex treatment (preventive and therapeutic measures) on the indicators of lipid-phospholipid fractions in patients with NASH in combination with obesity and pathology of the biliary tract was studied. Changes in the indicators of serum lipid-phospholipid fractions were detected before treatment in all observation groups, which were accompanied by decrease in phospholipids (PL), phosphatidylcholine and sphingomyelin content and a significant increase in PL lysoforms – lysophosphatidylcholine and phosphatidylethanolamine, triglycerides, cholesterol esters (from p<0.05 to p<0.001). Combination therapy with the inclusion in the standard treatment of ursodeoxycholic acid and arginine glutamate in the comorbid course of NASH can be considered as a promising direction in the treatment of this category of patients, this allows to improve indicators of lipid-phospholipid fractions and stabilize the hepatocytes’ membrane (from p<0.05 to p<0.001).
References
Veselova TA, Veselov AP, Deryugina AV. [Thin layer chromatography of lipids]. Uchebno-metodicheskoye posobiye. N. Novgorod: NNGU. 2015;23. Russian.
Goroshko OA, Kukes VG, Prokofiev AB, Arkhipov VV, Emchenkova YuE. [Clinical and pharmacological aspects of the use of antioxidant drugs]. International Journal of Applied and Fundamental Research. 2016;4-5:905-912. Russian.
Kryzhanovsky SP, Bogdanovich LN, Kushnerova NF, Shevchenko NM. [Phospholipids and neutral blood lipids in patients with dyslipidemia and their correction with polysaccharides from marine brown algae]. Fundamentalnye issledovaniya. 2014;10:1951-8. Russian.
Filippova OYu. [The relationship between biliary pathology and lipid-phospholipid changes in patients with nonalcoholic fatty liver disease and obesity]. Science Rise Medical Science. 2016;7(3):55-60. Ukrainian. doi: https://doi.org/10.15587/2519-4798.2016.74545
Filippova OYu. [Lipid-phospholipid disorders in patients with comorbid over nonalcoholic fatty liver disease and obesity on the background of pathology biliary tract depending on body weight]. Svit medytsyny ta biolohii. 2016;3(57):85-90. Ukrainian.
Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062-70. doi: https://doi.org/10.1016/j.cgh.2015.07.029
Nan YM, Fu N, Li WC, Kong LL, et.al. An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017. Zhonghua Gan. Zang. Bing. Za. Zhi. 2017;25(9):687-94. doi: https://doi.org/10.3760/cma.j.issn.1007-3418.2017.09.008
Della Corte C, Mazzotta AR, Nobili V. Fatty liver disease and obesity in youth. Curr Opin Endocrinol Diabetes Obes. 2016;23(1):66-71. doi: https://doi.org/10.1097/MED.0000000000000221
Filippova A. Non-alcoholic and alcoholic fatty liver disease in patients suffering from biliary tract pathology and obesity: clinical and functional aspects. Modern Science – Moderni vĕda. 2015;4:134-49.
Grechanyk M, Grechanyk N, Kuryata A. Lipid metabolism, endothelial function, parameters of elastic properties and inflammation in patients with coronary heart disease combined with hepatic steatosis depending from body mass index. Atherosclerosis. 2018;275:148. doi: https://doi.org/10.1016/j.atherosclerosis.2018.06.438/
Steinacher D, Claudel T, Trauner M. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. Dig. Dis. 2017;35(3):2822-87. doi: https://doi.org/10.1159/000454853
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2019 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
